Bavarian Nordic A/S : Bavarian Nordic Consolidates its Vaccine Manufacturing in Denmark

 Bavarian Nordic A/S : Bavarian Nordic Consolidates its Vaccine Manufacturing
                                  in Denmark

KVISTGAARD, Denmark, January 11, 2013 - Bavarian Nordic A/S (OMX: BAVA) today
announced that it will consolidate its manufacturing activities in Kvistgaard,
Denmark with an aim to optimize productivity and profitability. As part of
this consolidation, the company will prepare the Kvistgaard facility for the
future commercial production of its prostate cancer vaccine, PROSTVAC® and
also transfer its production of clinical trial material to the facility.
Consequently, the company will close its operations in Berlin, Germany where
it has been producing clinical trial material for its MVA-BN® based vaccine
candidates.

During 2012, Bavarian Nordic has steadily improved the efficiency in the
manufacturing of IMVAMUNE® smallpox vaccine at its commercial-scale facility
in Kvistgaard. Further work is ongoing to improve the manufacturing process
and the productivity, thus seeking to further improve the profitability of the
current and future expected contracts with the U.S. Government to manufacture
and deliver IMVAMUNE®.

To fully benefit from the in-house expertise in poxvirus-based vaccine
manufacturing as well as to optimize the use of the Kvistgaard facility,
Bavarian Nordic has decided to prepare the facility for the future commercial
production of PROSTVAC® as well as to move its production of clinical trial
material for the company's MVA-BN®-based development projects This allows
Bavarian Nordic for a more flexible manufacturing approach and reduces
dependence from subcontractors, thus providing the company full control of
pre-launch activities for PROSTVAC®. At the Kvistgaard facility, functions to
support the production development of PROSTVAC® are already in place and thus
the preparatory work requires only moderate investments.

The above does not affect the company's expectations for the 2012 full year
results.

Asger Aamund
Chairman of the Board

Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline targets
cancer and infectious diseases, and includes ten development programs. In
oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 trial and is being developed under a collaboration agreement
with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials,
PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the
company's lead program is IMVAMUNE®, a non-replicating smallpox vaccine
candidate that is being developed and supplied for emergency use to the U.S.
Strategic National Stockpile under a contract with the U.S. Government. For
more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. We undertake no
obligation to publicly update or revise forward-looking statements to reflect
subsequent events or circumstances after the date made, except as required by
law.

201301uk

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Bavarian Nordic A/S via Thomson Reuters ONE
HUG#1669512
 
Press spacebar to pause and continue. Press esc to stop.